title: Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a predominant pathogen resulting in significant morbidity and mortality. Optimal dosing of anti-MRSA agents is needed to help prevent the development of antimicrobial resistance and to increase the likelihood of a favorable clinical outcome. Areas covered: This review summarizes the available data for antimicrobials routinely used for MRSA infections that are not administered orally or topically. We make recommendations and highlight the current gaps in the literature. A PubMed (1966 - Present) search was performed to identify relevant literature for this review. Expert commentary: Improvements in MIC determination and therapeutic drug monitoring are needed to fully implement individualized dosing that optimizes antimicrobial pharmacodynamics.Additional data will become available for these agents in regards to effectiveness for severe MRSA infections and pharmacokinetic data for special patient populations.
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.|b Dose Optimization and Outcomes Research (DOOR) program.
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Hall
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Thatcher
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Shibin
authors.initials: S
authors.lastname: Varghese
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Lincy
authors.initials: L
authors.lastname: Varughese
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Ndiulor
authors.affiliation: a Texas Tech University Health Sciences Center , Dallas , TX , USA.
authors.forename: Kenna D
authors.initials: KD
authors.lastname: Payne
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods; D024881:Drug Resistance, Bacterial; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Dose optimization; MRSA; antimicrobial; pharmacodynamics; pharmacokinetics